文献速递甲状腺疾病

P21(CDKN1A)激活激酶4被鉴定为家族性非髓样甲状腺癌易感基因

Identification of P21 (CDKN1A) Activated Kinase 4 as a Susceptibility Gene for Familial Non-Medullary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2024-03-25

本研究在一个患甲状腺乳头状癌的五人家系中,通过全外显子组测序和Sanger测序鉴定PAK4 c.T1250C p.I417T突变为家族性非髓样甲状腺癌潜在易感基因。体外实验显示该突变增强细胞增殖、侵袭和抗凋亡,体内实验显示其具有显著转移倾向。作者认为突变型PAK4具有致癌功能,可能作为家族性非髓样甲状腺癌的新型诊断分子标志物。

要点

  • 在一个甲状腺乳头状癌家系中鉴定出PAK4 c.T1250C p.I417T突变。
  • 该突变促进PAK4磷酸化核转位,体外增强增殖、侵袭并抑制凋亡。
  • 作者认为突变型PAK4具有致癌功能,可能作为诊断分子标志物。

核心结论

  • 研究鉴定PAK4 c.T1250C p.I417T为家族性非髓样甲状腺癌的潜在易感基因。
  • 突变型PAK4表现出致癌功能,作者认为其可能作为家族性非髓样甲状腺癌的新型诊断分子标志物。

研究设计与样本

  • 研究纳入一个患甲状腺乳头状癌的五人家系。
  • 通过全外显子组测序和Sanger测序在家系成员、其他家族性非髓样甲状腺癌患者及散发性非髓样甲状腺癌患者中鉴定候选基因。
  • 采用计算机模拟工具预测突变致病性,并进行体外细胞表型实验和体内肺远处转移模型验证突变特征。
  • 通过转录组测序和机制验证比较PAK4野生型与PAK4突变型细胞系的差异。

主要发现

  • 该突变改变蛋白质结构,可能通过影响疏水性、分子内氢键和磷酸化位点增加不稳定性。
  • 该突变特异性促进磷酸化PAK4在甲状腺组织和细胞系中的核转位和表达。
  • 与野生型细胞系相比,PAK4 I417T在体外表现出增强的增殖、侵袭性、加速的细胞分裂和抑制细胞凋亡。
  • PAK4 I417T在体内表现出显著的转移倾向。
  • 与野生型通过PAK4-NFκ-MMP9轴激活不同,突变型通过增加PAK4、JNK、NFκB和c-Jun磷酸化激活肿瘤坏死因子信号;PAK4突变蛋白与MMP3相互作用并调节MMP3启动子活性,而野生型未观察到该现象。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Familial non-medullary thyroid carcinoma (FNMTC) is a genetically predisposed disease with unclear genetic mechanisms. This makes research on susceptibility genes important for the diagnosis and treatment options. Methods: This study included a five-member family affected by papillary thyroid carcinoma. The candidate genes were identified through whole-exome sequencing and Sanger sequencing in family members, other FNMTC patients, and sporadic non-medullary thyroid carcinoma patients. The pathogenicity of the mutation was predicted using in silico tools. Cell phenotype experiments in vitro and models of lung distant metastasis in vivo were conducted to confirm the characteristics of the mutation. Transcriptome sequencing and mechanistic validation were employed to compare the disparities between PAK4 wild-type (WT) and PAK4 mutant (MUT) cell lines. Results: This mutation alters the protein structure, potentially increasing instability by affecting hydrophobicity, intra-molecular hydrogen bonding, and phosphorylation sites. It specifically promotes phosphorylated PAK4 nuclear translocation and expression in thyroid tissue and cell lines. Compared with the WT cells line, PAK4 I417T demonstrates enhanced proliferation, invasiveness, accelerated cell division, and inhibition of cell apoptosis in vitro. In addition, it exhibits a significant propensity for metastasis in vivo. It activates tumor necrosis factor signaling through increased phosphorylation of PAK4, JNK, NFκB, and c-Jun, unlike the WT that activates it via the PAK4-NFκ-MMP9 axis. In addition, PAK4 MUT protein interacts with matrix metalloproteinase (MMP)3 and regulates MMP3 promoter activity, which is not observed in the WT. Conclusions: Our study identified PAK4: c.T1250C: p.I417T as a potential susceptibility gene for FNMTC. The study concludes that the mutant form of PAK4 exhibits oncogenic function, suggesting its potential as a novel diagnostic molecular marker for FNMTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jiang YJ, Xia Y, Hu YX, et al. Identification of P21 (CDKN1A) Activated Kinase 4 as a Susceptibility Gene for Familial Non-Medullary Thyroid Carcinoma. Thyroid. 2024. PMID: 38411500. doi:10.1089/thy.2023.0564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。